ARTICLE | Company News
Japan approves Revlimid for MDS
August 20, 2010 11:32 PM UTC
Japan's Ministry of Health, Labor and Welfare approved Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG) to treat myelodysplastic syndromes (MDS) in patients with 5q chromosomal deletion. In June...